CUREVAC NV (5CV.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:5CV • NL0015436031

3.892 EUR
+0.01 (+0.36%)
Last: Jan 5, 2026, 07:00 PM
Fundamental Rating

4

Taking everything into account, 5CV scores 4 out of 10 in our fundamental rating. 5CV was compared to 84 industry peers in the Biotechnology industry. 5CV has only an average score on both its financial health and profitability. 5CV does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • In the past year 5CV has reported negative net income.
  • In the past year 5CV has reported a negative cash flow from operations.
  • 5CV had negative earnings in 4 of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: 5CV reported negative operating cash flow in multiple years.
5CV.DE Yearly Net Income VS EBIT VS OCF VS FCF5CV.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M -600M -800M

1.2 Ratios

  • 5CV has a better Return On Assets (11.31%) than 84.34% of its industry peers.
  • With an excellent Return On Equity value of 14.79%, 5CV belongs to the best of the industry, outperforming 84.34% of the companies in the same industry.
  • The Return On Invested Capital of 5CV (14.12%) is better than 87.95% of its industry peers.
Industry RankSector Rank
ROA 11.31%
ROE 14.79%
ROIC 14.12%
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
5CV.DE Yearly ROA, ROE, ROIC5CV.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 -200

1.3 Margins

  • Looking at the Profit Margin, with a value of 182.11%, 5CV belongs to the top of the industry, outperforming 98.80% of the companies in the same industry.
  • Looking at the Operating Margin, with a value of 212.01%, 5CV belongs to the top of the industry, outperforming 98.80% of the companies in the same industry.
  • With an excellent Gross Margin value of 93.01%, 5CV belongs to the best of the industry, outperforming 86.75% of the companies in the same industry.
Industry RankSector Rank
OM 212.01%
PM (TTM) 182.11%
GM 93.01%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
5CV.DE Yearly Profit, Operating, Gross Margins5CV.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • 5CV has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • The number of shares outstanding for 5CV remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, 5CV has more shares outstanding
  • 5CV has a better debt/assets ratio than last year.
5CV.DE Yearly Shares Outstanding5CV.DE Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
5CV.DE Yearly Total Debt VS Total Assets5CV.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • An Altman-Z score of 4.17 indicates that 5CV is not in any danger for bankruptcy at the moment.
  • 5CV has a Altman-Z score of 4.17. This is in the better half of the industry: 5CV outperforms 73.49% of its industry peers.
  • 5CV has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
  • With a decent Debt to Equity ratio value of 0.03, 5CV is doing good in the industry, outperforming 69.88% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 4.17
ROIC/WACC1.96
WACC7.19%
5CV.DE Yearly LT Debt VS Equity VS FCF5CV.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 500M -500M

2.3 Liquidity

  • 5CV has a Current Ratio of 3.70. This indicates that 5CV is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 3.70, 5CV is in the better half of the industry, outperforming 69.88% of the companies in the same industry.
  • A Quick Ratio of 3.69 indicates that 5CV has no problem at all paying its short term obligations.
  • The Quick ratio of 5CV (3.69) is better than 73.49% of its industry peers.
Industry RankSector Rank
Current Ratio 3.7
Quick Ratio 3.69
5CV.DE Yearly Current Assets VS Current Liabilites5CV.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • The earnings per share for 5CV have decreased strongly by -247.92% in the last year.
  • 5CV shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -86.98%.
  • The Revenue has been growing by 98.42% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-247.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-105.33%
Revenue 1Y (TTM)-86.98%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-89.04%

3.2 Future

  • 5CV is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -22.50% yearly.
  • Based on estimates for the next years, 5CV will show a very negative growth in Revenue. The Revenue will decrease by -11.14% on average per year.
EPS Next Y-163.99%
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue Next Year-84.14%
Revenue Next 2Y-55.71%
Revenue Next 3Y-30.85%
Revenue Next 5Y-11.14%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
5CV.DE Yearly Revenue VS Estimates5CV.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
5CV.DE Yearly EPS VS Estimates5CV.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for 5CV. In the last year negative earnings were reported.
  • Also next year 5CV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
5CV.DE Price Earnings VS Forward Price Earnings5CV.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 5CV indicates a rather cheap valuation: 5CV is cheaper than 96.39% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 2.92
5CV.DE Per share data5CV.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

  • 5CV's earnings are expected to decrease with -28.72% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for 5CV!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CUREVAC NV

FRA:5CV (1/5/2026, 7:00:00 PM)

3.892

+0.01 (+0.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-24
Earnings (Next)04-08
Inst Owners10.45%
Inst Owner ChangeN/A
Ins Owners0.09%
Ins Owner ChangeN/A
Market Cap876.36M
Revenue(TTM)70.74M
Net Income(TTM)128.82M
Analysts74.55
Price Target4.02 (3.29%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.69%
Min EPS beat(2)-39.67%
Max EPS beat(2)30.28%
EPS beat(4)2
Avg EPS beat(4)1.84%
Min EPS beat(4)-39.67%
Max EPS beat(4)35.41%
EPS beat(8)3
Avg EPS beat(8)1.3%
EPS beat(12)5
Avg EPS beat(12)-6.32%
EPS beat(16)8
Avg EPS beat(16)6.13%
Revenue beat(2)1
Avg Revenue beat(2)149.77%
Min Revenue beat(2)-96.47%
Max Revenue beat(2)396.01%
Revenue beat(4)2
Avg Revenue beat(4)82.72%
Min Revenue beat(4)-96.47%
Max Revenue beat(4)396.01%
Revenue beat(8)5
Avg Revenue beat(8)103.01%
Revenue beat(12)5
Avg Revenue beat(12)58%
Revenue beat(16)8
Avg Revenue beat(16)71.24%
PT rev (1m)-2.38%
PT rev (3m)-4.19%
EPS NQ rev (1m)0%
EPS NQ rev (3m)966.6%
EPS NY rev (1m)9.31%
EPS NY rev (3m)2.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)33.33%
Revenue NY rev (1m)19.7%
Revenue NY rev (3m)20.12%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.39
P/FCF N/A
P/OCF N/A
P/B 1.01
P/tB 1.04
EV/EBITDA 2.92
EPS(TTM)-0.71
EYN/A
EPS(NY)-0.44
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.53
OCFYN/A
SpS0.31
BVpS3.87
TBVpS3.76
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 11.31%
ROE 14.79%
ROCE 16.62%
ROIC 14.12%
ROICexc 26.37%
ROICexgc 27.79%
OM 212.01%
PM (TTM) 182.11%
GM 93.01%
FCFM N/A
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA 0.18
Cap/Depr 28.09%
Cap/Sales 7.01%
Interest Coverage 66.45
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.7
Quick Ratio 3.69
Altman-Z 4.17
F-Score3
WACC7.19%
ROIC/WACC1.96
Cap/Depr(3y)242.45%
Cap/Depr(5y)397%
Cap/Sales(3y)81.47%
Cap/Sales(5y)93.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-247.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-105.33%
EPS Next Y-163.99%
EPS Next 2Y-61.18%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue 1Y (TTM)-86.98%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-89.04%
Revenue Next Year-84.14%
Revenue Next 2Y-55.71%
Revenue Next 3Y-30.85%
Revenue Next 5Y-11.14%
EBIT growth 1Y13.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-158.29%
EBIT Next 3Y-29.43%
EBIT Next 5Y10.78%
FCF growth 1Y62.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y56.06%
OCF growth 3YN/A
OCF growth 5YN/A

CUREVAC NV / 5CV.DE FAQ

Can you provide the ChartMill fundamental rating for CUREVAC NV?

ChartMill assigns a fundamental rating of 4 / 10 to 5CV.DE.


What is the valuation status of CUREVAC NV (5CV.DE) stock?

ChartMill assigns a valuation rating of 3 / 10 to CUREVAC NV (5CV.DE). This can be considered as Overvalued.


Can you provide the profitability details for CUREVAC NV?

CUREVAC NV (5CV.DE) has a profitability rating of 5 / 10.


What is the financial health of CUREVAC NV (5CV.DE) stock?

The financial health rating of CUREVAC NV (5CV.DE) is 6 / 10.